SUBSCRIBE
SUBSCRIBE
News   Drug Development

First Patient Treated in BioInvent’s Phase I Study of the Drug Candidate BI-505 to Treat Multiple Myeloma

January 4, 2010 | 
1 min read
Bookmark and Share

LUND, Sweden--(BUSINESS WIRE)--BioInvent International AB (STO:BINV) announced today that the first patient has been treated in an open, dose-escalation phase I study of the company’s antibody BI-505 for patients with advanced multiple myeloma.
Clinical research Phase I Europe
MORE ON THIS TOPIC
Relay race. Concept of teamwork. working together of business. Vector illustration
Clinical Research
Terns Climbs 10% As ‘Unprecedented’ Leukemia Data Beats Novartis’ Scemblix
December 9, 2025
 · 
3 min read
 · 
Annalee Armstrong
Art collage, coins, and arrow up on the red and paper background. Concept of business and financial growth.
Obesity
Structure Stock Soars as Oral GLP-1 Generates ‘Highly Competitive’ Weight Loss
December 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Stand out from the crowd and different creative idea concepts , Longest light ladder glowing and aiming high to goal target among other short ladders on green background with shadows . 3D rendering.
Infectious disease
Assembly’s Antivirals Show ‘Striking’ Drop in Lesions, Viral Shedding in Early Genital Herpes Study
December 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Hands, tablet and doctor with body hologram, overlay and dna research for medical innovation on app. Medic man, nurse and mobile touchscreen for typing on anatomy study or 3d holographic ux in clinic
Policy
As FDA Deploys Agentic AI, Pharma Begins Testing the Next Frontier of Intelligent Automation
December 8, 2025
 · 
3 min read
 · 
Jennifer Smith-Parker